Bristol, Exelixis Trials Preview Changes In Kidney Cancer Market
This article was originally published in The Pink Sheet Daily
Commenting on pivotal trial success for Bristol’s checkpoint immunotherapy Opdivo and targeted Cometriq in renal cancer, Exelixis CEO Michael Morrissey says there’s room for two new different drugs for kidney cancer, and points out that an early stage study combining them is under way.
You may also be interested in...
Cometriq Thyroid Approval May Open Door For Use In Prostate Cancer
As cabozantinib wins FDA approval for the rare medullary thyroid cancer, Exelixis stresses its broader development program in other tumor types, notably prostate cancer. The company is likely to submit prostate cancer data to compendia, which if successful could enable reimbursement for the off-label use.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.